Evidence map›Paper›PMID 42848083›Full record

ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2026

Feasibility of clinical implementation and acceptability of patient-reported screening for chemotherapy-induced peripheral neuropathy (CIPN).

Alice Treloar, Peter Grimison, Victoria Choi, Jed Young, Katelin Mayer, Tiffany Li, Frances Boyle, Tracy King, David Mizrahi, Lisa G Horvath and 2 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Alice TreloarBrain and Mind Centre, The University of Sydney, Sydney, NSW, Australia.
Peter GrimisonChris O'Brien Lifehouse, Sydney, NSW, Australia.
Victoria ChoiChris O'Brien Lifehouse, Sydney, NSW, Australia.
Jed YoungPrince of Wales Hospital, Sydney, NSW, Australia.
Katelin MayerPrince of Wales Hospital, Sydney, NSW, Australia.
Tiffany LiBrain and Mind Centre, The University of Sydney, Sydney, NSW, Australia.
Frances BoyleSydney Medical School, The University of Sydney, Sydney, NSW, Australia.
Tracy KingInstitute of Haematology, Royal Prince Alfred Hospital, Sydney, NSW, Australia.
David MizrahiThe Daffodil Centre, The University of Sydney, and Cancer Council NSW, Sydney, NSW, Australia.
Lisa G HorvathChris O'Brien Lifehouse, Sydney, NSW, Australia.
David GoldsteinPrince of Wales Hospital, Sydney, NSW, Australia.
Susanna B ParkBrain and Mind Centre, The University of Sydney, Sydney, NSW, Australia. Susanna.Park@sydney.edu.au.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeChemotherapy-induced peripheral neuropathy (CIPN) is a major side-effect of cancer treatment, leading to early treatment cessation and long-lasting disability. This project aimed to determine acceptability and barriers of routine CIPN screening.

methodsIn a prospective sample across two sites, patients scheduled for treatment or treated with neurotoxic therapy were eligible to complete CIPN screening at any cycle. Three brief patient-reported outcome screening tools (NCI-PRO-CTCAE, PNQ, and EviQ) and a short feasibility questionnaire were deployed (termed CIPN-Screen) during appointments (Centre 1) or via automated text messages (Centre 2).

resultsSeven hundred fifty-five screens were undertaken in 159 participants between March 2022 and November 2023, with 109 at Centre 1 (median[IQR] 1[1]screen) and 646 at Centre 2 (median[IQR] 8[6]screens). Automatic text message reminders at Centre 2 enabled longitudinal assessments to be collected. 426 screens (56.4%) identified CIPN symptoms with 138 (18.3%) moderate-to-severe. Most respondents reported that the CIPN-Screen was easy to complete (92.0%, n = 671), easy to understand (91.6%, n = 668), and helpful to describe symptoms (85.6%, n = 624). Acceptability did not differ by age, sex, or chemotherapy type; however, acceptability did differ according to CIPN symptom severity (P = 0.0002). There were significant differences in CIPN symptom score over time (P < 0.0001, n = 52), indicating that the CIPN-Screen detected symptom evolution over time.

conclusionQuestionnaire-based CIPN screening is feasible and assists in symptom profiling for patients treated with neurotoxic chemotherapy. IMPLICATIONS FOR CANCER SURVIVORS: CIPN is an important toxicity with lasting effects for cancer survivors. Identifying better approaches to patient-relevant CIPN screening will enable improved care for cancer survivors.

Indexed as

Antineoplastic AgentsMass ScreeningPeripheral Nervous System DiseasesAdultAgedFeasibility StudiesFemaleHumansMaleMiddle AgedNeoplasmsPatient Reported Outcome MeasuresProspective StudiesSurveys and QuestionnairesAntineoplastic AgentsCancerChemotherapy induced peripheral neuropathyCIPNQuality of lifeScreening

Identifiers

PMID42848083

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.